Skip to main content
Premium Trial:

Request an Annual Quote

Quest Launches Microarray-Based Test for Chromosome Abnormalities

Quest Diagnostics today said that it is now offering a molecular diagnostic test that can detect chromosome abnormalities associated with 85 developmental disorders affecting children.
 
The ClariSure is a microarray-based comparative genomic hybridization test that will be used to diagnose patients with mental retardation and Down syndrome among other disorders. Quest said it expects to provide physicians with test results within five days of receiving specimens at one of its facilities.
 
The test is based on technologies developed by Quest’s Nichols Institute and other licensed methodologies.
 
“While CGH microarrays are often used for research purposes, the considerable expertise and development required to commercialize these technologies has limited their use for diagnostic testing,” Joyce Schwartz, vice president and chief laboratory officer for Quest, said in a statement. She said the ClariSure assay “bridges the gap” between scientific research and clinical diagnostic testing and provides a faster diagnosis of developmental disorders.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.